JP2019501925A5 - - Google Patents

Download PDF

Info

Publication number
JP2019501925A5
JP2019501925A5 JP2018535388A JP2018535388A JP2019501925A5 JP 2019501925 A5 JP2019501925 A5 JP 2019501925A5 JP 2018535388 A JP2018535388 A JP 2018535388A JP 2018535388 A JP2018535388 A JP 2018535388A JP 2019501925 A5 JP2019501925 A5 JP 2019501925A5
Authority
JP
Japan
Prior art keywords
composition
subject
gdf11 polypeptide
gdf11
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018535388A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501925A (ja
JP6948331B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/012505 external-priority patent/WO2017120450A1/en
Publication of JP2019501925A publication Critical patent/JP2019501925A/ja
Publication of JP2019501925A5 publication Critical patent/JP2019501925A5/ja
Priority to JP2021126586A priority Critical patent/JP7288012B2/ja
Application granted granted Critical
Publication of JP6948331B2 publication Critical patent/JP6948331B2/ja
Priority to JP2022193543A priority patent/JP2023014339A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018535388A 2016-01-06 2017-01-06 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する Active JP6948331B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021126586A JP7288012B2 (ja) 2016-01-06 2021-08-02 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する
JP2022193543A JP2023014339A (ja) 2016-01-06 2022-12-02 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662275645P 2016-01-06 2016-01-06
US62/275,645 2016-01-06
PCT/US2017/012505 WO2017120450A1 (en) 2016-01-06 2017-01-06 Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021126586A Division JP7288012B2 (ja) 2016-01-06 2021-08-02 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する

Publications (3)

Publication Number Publication Date
JP2019501925A JP2019501925A (ja) 2019-01-24
JP2019501925A5 true JP2019501925A5 (https=) 2020-02-13
JP6948331B2 JP6948331B2 (ja) 2021-10-13

Family

ID=59273941

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018535388A Active JP6948331B2 (ja) 2016-01-06 2017-01-06 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する
JP2021126586A Active JP7288012B2 (ja) 2016-01-06 2021-08-02 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する
JP2022193543A Pending JP2023014339A (ja) 2016-01-06 2022-12-02 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021126586A Active JP7288012B2 (ja) 2016-01-06 2021-08-02 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する
JP2022193543A Pending JP2023014339A (ja) 2016-01-06 2022-12-02 Gdf11での処置は、体重増加を防止し、耐糖能を改善し、そして脂肪肝を低減する

Country Status (8)

Country Link
US (3) US10980857B2 (https=)
EP (2) EP3399998B1 (https=)
JP (3) JP6948331B2 (https=)
CN (2) CN109310742B (https=)
CA (1) CA3010799A1 (https=)
ES (1) ES2893813T3 (https=)
IL (4) IL301476A (https=)
WO (1) WO2017120450A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2983694B1 (en) 2013-04-08 2022-06-22 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
CA3010799A1 (en) 2016-01-06 2017-07-13 President And Fellows Of Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
CN108619492A (zh) * 2018-05-31 2018-10-09 暨南大学 Gdf11在制备用于治疗肥胖的产品中的应用及治疗肥胖的产品
US10804162B2 (en) 2018-09-27 2020-10-13 Taiwan Semiconductor Manufacturing Co., Ltd. Dual channel gate all around transistor device and fabrication methods thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
BR9406715A (pt) 1993-05-12 1996-02-06 Genetics Inst Molécula de DNA isolada célula hospedeira vetor método para produzir uma proteina (BMP-11) polipeptideo de proteina-11 morfogenética de osso purificada (BMP-11) e molécula de DNA quimérica
CA2194660C (en) 1994-07-08 2009-09-29 Se-Jin Lee Growth differentiation factor-11
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
US6008434A (en) 1994-07-08 1999-12-28 Johns Hopkins University School Of Medicine Growth differentiation factor-11 transgenic mice
CA2291514C (en) 1997-05-30 2011-07-12 Mariel Therapeutics, Inc. Methods for evaluating tissue morphogenesis and activity
US6891082B2 (en) * 1997-08-01 2005-05-10 The Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a truncated activintype II receptor
US6696260B1 (en) 1997-08-01 2004-02-24 The Johns Hopkins University School Of Medicine Methods to identify growth differentiation factor (GDF) binding proteins
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US7795202B2 (en) 1997-08-04 2010-09-14 Neurorepair, Inc. Methods for treating a neurological disorder by peripheral administration of a transforming growth factor alpha (TGF-a)
US6953662B2 (en) 1997-08-29 2005-10-11 Human Genome Sciences, Inc. Follistatin-3
AU1276399A (en) 1997-11-07 1999-05-31 Genetics Institute Inc. Neuronal uses of bmp-11
US20030170213A1 (en) 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
ES2318900T3 (es) 1998-07-15 2009-05-01 Metamorphix, Inc. Promotor del factor de diferenciacion del crecimiento y sus usos.
US7572440B2 (en) 1999-07-30 2009-08-11 Stryker Corporation Method for repairing a defect in an intervertebral disc
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US20030104977A1 (en) 2000-03-31 2003-06-05 Ugo Ripamonti Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
TWI329129B (en) * 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
EP1790726B1 (en) 2001-02-08 2013-07-03 Wyeth LLC Modified and stabilized GDF propeptides and uses thereof
US20060078532A1 (en) 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease
WO2004073633A2 (en) * 2003-02-14 2004-09-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating the development of stem cells
NZ529860A (en) 2003-11-28 2006-10-27 Ovita Ltd Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
ATE557042T1 (de) 2004-03-23 2012-05-15 Lilly Co Eli Anti-myostatin-antikörper
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US20060216279A1 (en) 2005-03-22 2006-09-28 Glass David J Myostatin inhibiting fusion polypeptides and therapeutic methods thereof
NL1031674C2 (nl) 2005-04-25 2007-04-26 Pfizer Antilichamen tegen myostatine.
US20090215671A1 (en) 2005-05-27 2009-08-27 The Regents Of The University Of California Compositions And Methods For Treatment of Neural Disorders Using Transforming Growth Factor-Beta Superfamily Proteins And Their Antagonists
ES2534760T3 (es) 2005-08-19 2015-04-28 Wyeth Llc Anticuerpos antagonistas contra GDF-8 y sus usos en el tratamiento de ELA y otros trastornos asociados con GDF-8
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US7972599B2 (en) 2006-03-20 2011-07-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Immunomodulation of inflammatory conditions utilizing Follistatin-like protein-1 and agents that bind thereto
US20080044387A1 (en) 2006-03-24 2008-02-21 The Regents Of The University Of California Artificial niches for enhancement of regenerative capacity of stem cells in aged and pathological environments
EP2035030A2 (en) 2006-05-17 2009-03-18 Stryker Corporation Use of a soluble morphogenic protein complex for treating cartilage defects
US8168169B2 (en) 2006-08-09 2012-05-01 Mclean Hospital Corporation Methods and compositions for the treatment of medical disorders
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
US8404656B2 (en) 2007-08-09 2013-03-26 Children's Hospital Medical Center Methods of treatment and prevention of diet-induced obesity and sequelae thereof
CN102056617A (zh) 2008-03-20 2011-05-11 特兰斯莫莱库拉公司 血管生成的抑制
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
US8969081B2 (en) 2008-12-10 2015-03-03 The Trustees Of Columbia University In The City Of New York Caudal motor neuron derived from embryonic stem cells under conditions essentially free of any retinoid
EP2401293B1 (en) 2009-02-24 2016-02-10 The Salk Institute For Biological Studies Designer ligands of tgf-beta superfamily
WO2011130347A2 (en) 2010-04-13 2011-10-20 The Johns Hopkins University Methods for enhancing axonal regeneration
WO2012135623A1 (en) 2011-03-31 2012-10-04 Theravasc Inc. Use of nitrites for the treatment of cerebral amyloid angiopathy, age associated dementia, and cognitive decline
US8765385B2 (en) * 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
WO2013142114A1 (en) 2012-03-19 2013-09-26 The Brigham And Women's Hosptial, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
EP2983694B1 (en) 2013-04-08 2022-06-22 President and Fellows of Harvard College Compositions for rejuvenating skeletal muscle stem cells
EP3881859B1 (en) 2013-06-11 2024-03-06 President and Fellows of Harvard College Compositions for increasing neurogenesis and angiogenesis
SG11201510177WA (en) 2013-06-11 2016-01-28 Harvard College SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
EP4549947A3 (en) 2013-09-03 2025-05-21 Mayo Foundation for Medical Education and Research Reducing the risk of major adverse cardiac events
WO2015070076A2 (en) 2013-11-08 2015-05-14 President And Fellows Of Harvard College Methods and compositions for rejuvenating neuromuscular junctions
US10017566B2 (en) 2013-11-12 2018-07-10 The Brigham And Women's Hospital, Inc. Growth differentiation factor (GDF) for treatment of diastolic heart failure
US20170073406A1 (en) 2014-05-06 2017-03-16 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2016049662A1 (en) 2014-09-23 2016-03-31 President And Fellows Of Harvard College Methods and compositions for treating age-related disorders
CA3010799A1 (en) 2016-01-06 2017-07-13 President And Fellows Of Harvard College Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis
US10941195B2 (en) 2016-10-04 2021-03-09 Fairbanks Pharmaceuticals, Inc. Anti-follistatin-like 3 antibodies and treatment of diabetes
WO2019144053A1 (en) 2018-01-19 2019-07-25 President And Fellows Of Harward College Gdf11 variants and uses thereof

Similar Documents

Publication Publication Date Title
Kondo et al. A long-term study of istradefylline safety and efficacy in patients with Parkinson disease
JP2015187125A5 (https=)
Garay et al. Therapeutic perspectives on uricases for gout
JP2016516073A5 (https=)
JP2019501925A5 (https=)
JP2017529382A5 (https=)
Becker Sclerostin inhibition for osteoporosis–a new approach
JP2018521964A5 (https=)
JP2018531938A5 (https=)
JP2016514132A5 (https=)
JP2016516016A5 (https=)
JP2017533201A5 (https=)
JP6889154B2 (ja) グルカゴン類似ペプチド−1受容体亢進剤を含む筋減少症治療用薬学組成物
CA2939464A1 (en) Use of anti-ccr5 antibodies in graft versus host disease
JP2021509916A5 (https=)
JP5981141B2 (ja) 多臓器不全症候群(mods)の予防および/または処置のためのインターロイキン−22の使用
JP2018530525A5 (https=)
Zhang et al. The use of nicardipine for electroconvulsive therapy: a dose-ranging study
Toyooka et al. Iatrogenic neuropathies
Cetin et al. Paradigm shift in obesity treatment: an extensive review of current pipeline agents
JP2016510738A5 (https=)
US20140162958A1 (en) Copolymer-1 Composition and Methods of Use
Chou et al. Rapid development of severe skin rash after adding valproic acid in a case of bipolar depression treated with low-dose lamotrigine
WO2018079701A1 (ja) ラクトフェリン活性を有するタンパク質を含む、抗ガン治療補助剤
Ivaskevicius et al. Inhibitor development and management in three non-severe haemophilia A patients with T295A variant